GlassScriptPhysician profile
Phillip M King
NPI 1649621103
$5,474.75
in general payments reported to CMS, 2019-2025
27 companies · $2,535 in 2025
The $2,535 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $327 · 2021: $509 · 2022: $525 · 2023: $478 · 2024: $1,101 · 2025: $2,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,729 · Consulting Fee: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,729.29 |
| Consulting Fee | $1,384.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $1,487.52 | 2025 | Attruby |
| Abbott Laboratories | $1,179.75 | 2020-2025 | Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $481.56 | 2022-2025 | Camzyos, Eliquis |
| Abiomed | $304.48 | 2024 | Impella |
| Pfizer INC. | $301.22 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $276.40 | 2022-2023 | Uptravi, Opsumit |
| Cvrx, INC. | $194.87 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $174.48 | 2024-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $154.31 | 2024-2025 | |
| Philips North America LLC | $122.77 | 2021 | |
| Amgen INC. | $112.98 | 2024-2025 | Repatha, Repatha |
| Zoll Circulation INC | $111.17 | 2020 | |
| Merck Sharp & Dohme LLC | $69.12 | 2024-2025 | Verquvo |
| Kestra Medical Technology Services, INC. | $61.77 | 2024-2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $55.08 | 2025 | Amvuttra, Onpattro |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $45.50 | 2024 | Watchman Flx |
| Medtronic, INC. | $45.00 | 2022 | |
| Heartflow, INC. | $43.07 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.87 | 2023-2025 | Lifevest |
| Esperion Therapeutics, INC. | $40.20 | 2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.92 | 2025 | Jardiance |
| Inspire Medical Systems, INC. | $28.24 | 2024 | Inspire |
| Lantheus Medical Imaging, INC. | $24.78 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.58 | 2025 | |
| Scpharmaceuticals INC. | $21.59 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $20.00 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $18.52 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.